TAXANES

作品数：39被引量：101H指数：6
导出分析报告
相关领域：医药卫生更多>>
相关作者：胡益明甘烦远沈月毛鲁春华赵鑫更多>>
相关机构：福建中医学院中国科学院北京协和医学院法玛西雅意大利公司更多>>
相关期刊：《Discussion of Clinical Cases》《Chinese Journal of Cancer Research》《Synthetic and Systems Biotechnology》《Chinese Journal of Natural Medicines》更多>>
相关基金：国家自然科学基金云南省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Paclitaxel for second-line treatment of squamous cell carcinoma of the head and neck:A multicenter retrospective Italian study
《World Journal of Clinical Oncology》2024年第12期1468-1480,共13页Morena Fasano Mario Pirozzi Pasquale Vitale Vincenzo Damiano Graziana Ronzino Stefano Farese Vincenzo Carfora Giuseppina Ciccarelli Ilaria Di Giovanni Sergio Facchini Gregorio Cennamo Michele Caraglia Fortunato Ciardiello Raffaele Addeo 
BACKGROUND Squamous cell carcinoma of the head and neck(SCCHN)accounts for 3%of all malignant tumors in Italy.Immune checkpoint inhibitors combined with chemotherapy is first-line treatment for SCCHN;however,second-li...
关键词：TAXANES Immunotherapy Head and neck cancer Alcohol SMOKING Body mass index 
Cancer nuclear envelope rupture and repair in taxane resistance
《Medical Review》2024年第6期522-530,共9页Ana P.Xu Lucy B.Xu Elizabeth R.Smith Joshua S.Fleishman Zhe-Sheng Chen Xiang-Xi Xu 
partially supported by NIH funding R01 CA095071,CA79716,and CA75389 to XX from NCI,NIH;seed funding from Sylvester Comprehensive Cancer Center,University of Miami.
Taxanes,including paclitaxel,docetaxel,and cabazitaxel,are key agents in cancer treatment,often used as frontline chemotherapy drugs in combination with other agent(s)(commonly carboplatin)and as second-line treatment...
关键词：chemotherapy drug resistance TAXANES PACLITAXEL MICROTUBULES nuclear envelope 
Biochemical synthesis of taxanes from mevalonate
《Synthetic and Systems Biotechnology》2024年第4期694-700,共7页Jing Li Xiaonan Liu Xiaoxi Zhu Jiayu Liu Lei Zhang Nida Ahmed Jian Qi Bihuan Chen Daliang Tang Jinsheng Yu Zhijin Fan Huifeng Jiang 
supported in part by the National Natural Science Foundation of China(32371499,31901026 and 32172443),China Postdoctoral Science Foundation(2019M661032);National Key R&D Program of China(2020YFA0908000 and 2022YFD1700400);the Frontiers Science Center for New Organic Matter,Nankai University(63181206);he Tianjin Development Program for Innovation and Entrepreneurship(2019-06).
Taxanes are kinds of diterpenoids with important bioactivities,such as paclitaxel(taxol®)is an excellent natural broad-spectrum anticancer drug.Attempts to biosynthesize taxanes have made with limited success,mainly d...
关键词：Biochemical synthesis TAXANES PACLITAXEL Modular synthesis 
Targeting cell cycle regulators:A new paradigm in cancer therapeutics
《BIOCELL》2024年第12期1639-1666,共28页GARIMA SINGH SONIKA KUMARI SHARMA NEELU MISHRA AASTHA SONI MANSHI KUMARI SAMARENDRA KUMAR SINGH 
Dysregulation of the cell cycle is a molecular hallmark of cancer,which leads to uncontrolled proliferation and self-renewal of neoplastic cells.To maintain this phenotype,cells acquire multiple molecular alterations ...
关键词：CYCLINS Cyclin-dependent kinases TAXANES Cell cycle inhibitors Targeted therapy 
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase Ⅱ single-arm study
《Chinese Journal of Cancer Research》2024年第1期55-65,共11页Yaping Yang Liang Jin Yudong Li Nanyan Rao Chang Gong Shunrong Li Jiannan Wu Jinghua Zhao Linxiaoxiao Ding Fengxia Gan Jun Zhang Ruifa Feng Zhenzhen Liu Qiang Liu 
supported by the National Natural Science Foundation of China (No. 82003311, No. 82061148016, No. 82230057 and No. 82272859);National Key R&D Program of China (No. 2022YFC2505101);Sun Yat-Sen Clinical Research Cultivating Program (No. SYS-Q202004);Beijing Medical Award Foundation (No. YXJL2020-0941-0760);Guangzhou Science and Technology Program (No. 202102010272 and No. 202201020486)。
Objective: Despite cardiotoxicity overlap, the trastuzumab/pertuzumab and anthracycline combination remains crucial due to significant benefits. Pegylated liposomal doxorubicin(PLD), a less cardiotoxic anthracycline, ...
关键词：Breast cancer HER2-positive breast cancer dual HER2 blockade neoadjuvant therapy sequential therapy 
Probing the new strategy for the oral formulations of taxanes:changing the method with the situation被引量：2
《Chinese Journal of Natural Medicines》2021年第9期656-665,共10页WANG He-Lin SUN Jin TIAN Chu-Tong HE Zhong-Gui 
The first-generation taxanes(including paclitaxel and docetaxel)are widely used for the treatment of various cancers in clinical settings.In the past decade,a series of new-generation taxanes have been developed which...
关键词：TAXANES Oral delivery Oral bioavailability ANTI-TUMOR 
Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301,a nanoparticle of docetaxel
《Cancer Drug Resistance》2020年第3期636-646,共11页Eiman Mukhtar Daniel Worroll Giuseppe Galletti Shelly Schuster Sarina A.Piha-Paul Paraskevi Giannakakou 
Aim:We reviewed the radiographic response of three patients with metastatic castration-resistant prostate cancer treated with CRXL301,a docetaxel nanoparticle.For these three patients,we isolated and analyzed circulat...
关键词：Liquid biopsy circulating tumor cells castration-resistant prostate cancer MICROTUBULES TAXANES biomarkers 
Methylated PLK2 is a prognostic biomarker in taxane-treated breast cancers
《Discussion of Clinical Cases》2020年第2期7-12,共6页Priti Chivers Laura Lattanzio Ornella Garrone Daniela Vivenza Nel Syed Marco C.Merlano Tim Crook Helen M.Coley Cristiana Lo Nigro 
funding from Breast Cancer Campaign UK for a grant to support this work(HMC).
Background:In search of potential biomarkers of drug responsiveness the tumour suppressor PLK2 has been identified as a mediator of taxane sensitivity in some tumour types,based on its role of G2M checkpoint regulatio...
关键词：Breast cancer PLK2 DNA methylation Drug resistance TAXANES 
Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China被引量：7
《Cancer Communications》2020年第6期260-269,共10页Zongbi Yi Fei Ma Guohua Rong Yanfang Guan Chunxiao Li Binghe Xu 
supported by the grants from the Chinese Academy of Medical Sciences(CAMS)Initiative for InnovativeMedicine(CAMS-12 M-1-010,2017-I2M-3-004);the National Natural Science Foundation of China(81874122).
Background:TP53 mutations are common in breast cancer.There is currently no large-scale cohort study to investigate the TP53 landscape in breast cancer patients from China.The predictive value of TP53 mutations for th...
关键词：breast cancer TP53 mutation circulating tumor DNA next-generation sequencing Chinese prognosis trastuzumab TAXANES 
Impact of taxanes on androgen receptor signaling被引量：1
《Asian Journal of Andrology》2019年第3期249-252,共4页Shanshan Bai Bryan Y Zhang Yan Dong 
the following grants: National Institutes ofHealth/National Cancer Institute (NIH/NCI) RO1 CAI88609, Department of Defense W81XWH-15-1-0439, W81XWH-16-1-0317, and W81XWH-14-1-0485;National Natural Science Foundation of China Project 81430087.
The development and progression of metastatic castration-resistant prostate cancer is the major challenge in the treatment of advanced prostate cancer. The androgen receptor signaling pathway remains active in metasta...
关键词：ANDROGEN RECEPTOR ANDROGEN RECEPTOR splice variant CABAZITAXEL DOCETAXEL prostate cancer TAXANE 
全选清除导出
共4页<1234>
检索报告 对象比较 聚类工具 使用帮助 返回顶部